DiCE Molecules is a privately-held company focused on the development of small molecule compounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. Utilizing its unique approach, DiCE can amplify the strongest potential drug candidates and, by combining massive diversity with amplification and selection, substantially increase the probability of success.
View Top Employees from DiCE Molecules| Website | http://www.dicemolecules.com |
| Revenue | $8 million |
| Funding | $80 million |
| Employees | 81 (81 on RocketReach) |
| Founded | 2013 |
| Address | 279 E Grand Ave, Ste 300 Lobby B, South San Francisco, California 94080, US |
| Industry | Biotechnology, Pharmaceuticals, Discovery Tools (Healthcare), Healthcare |
| Web Rank | 7 Million |
| Keywords | Dice Molecules, Dice Therapeutics |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 5417 Companies, NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies |
Looking for a particular DiCE Molecules employee's phone or email?
DiCE Molecules Questions
The DiCE Molecules annual revenue was $8 million in 2023.
Jeffrey Enejosa is the Vice President, Clinical Development of DiCE Molecules.
81 people are employed at DiCE Molecules.
DiCE Molecules is based in South San Francisco, California.
The NAICS codes for DiCE Molecules are [5417, 541714, 541, 54, 54171].
The SIC codes for DiCE Molecules are [87, 873].
Top DiCE Molecules Employees
-
5+5+
-
View
Kevin Judice
Senior Vice President, Lilly Research Laboratories, and CEO of DICE Therapeutics at DiCE Molecules
South San Francisco, CA, US55 -
View
Mike Schwaebe
Vice President, Process Chemistry, DICE Therapeutics at DiCE Molecules
San Diego, California, United States35+ -
21
-
21
-
23
-
31
-
35+
Related Companies
